Skip to main content
FDA grants breakthrough therapy designation for new Gazyva indication
9/19/2019

Roche's Gazyva, or obinutuzumab, approved as a treatment for
lymphoma, was granted breakthrough therapy designation for a new indication, lupus nephritis. Data supporting the status granted by the FDA was based on results from a midstage trial that showed use of Gazyva in combination with existing standard of care was superior to placebo in terms of complete renal response at 12 months.

Full Story: